Coronavirus stocks were on the move in after-hours trading on February 12, 2020.
5 Coronavirus Stocks With Explosive Potential
APT Stock was up more than 17% in after-hours trade on February 12, 2020.
On February 3, 2020, Alpha Pro Tech announced that the company is exponentially ramping up production of its N-95 Particulate Respirator face mask in response to a significant increase in customer demand and level of orders resulting from the outbreak of the novel Wuhan coronavirus and the declaration by the World Health Organization of the outbreak as a “public health emergency of international concern.” CEO Hoffman said, “In addition to N-95 face masks, demand for face shields and other personal protective equipment products is increasing. The company is monitoring inventory levels across our full line of PPE products and will take appropriate steps to increase production to respond to consumer demand.”
NNVC stock was up more than 13% in after-hours trading.
On January 30, 2020, NanoViricides is confirming public disclosures in articles by various industry journals and other articles, that it is working on developing a treatment for the novel coronavirus 2019-nCoV, or the Wuhan coronavirus. “We have already initiated a program for developing a treatment for the 2019-nCOV,” said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, “Our platform technology enables possibly the most rapid pathway for new drug development against viral diseases. Of course, we will need support from governmental and international agencies such as the US CDC, WHO, and Chinese CDC to successfully develop these treatments, and, if developed, to get them to the patients in the fastest possible time. At this time, the Company does not have a collaboration with any of these agencies, and we have not been contacted by any of these entities or asked to develop a treatment for this virus. We had collaborations with the CDC and USAMRIID in the past. The Company intends to pursue a relevant collaboration for testing of our drug candidates soon.” The new 2019-nCoV is known to be closely related to the SARS-CoV of 2002-2003 epidemic. In fact it has been shown to use the same cell surface receptor as SARS-CoV, namely ACE2. “We have already found some lead candidate ligands in our chemical library that can bind to the SARS-CoV spike protein in the same fashion as it binds to the cognate receptor, ACE2, using molecular modeling tools,” explained Dr. Diwan, adding, “We believe this means we may already be significantly ahead in developing a potential treatment for the new Wuhan virus.”
VXRT stock was up over 10% in after-hours trading on February 12, 2020.
On January 31, 2020, Vaxart announced that it has initiated a program to develop a coronavirus vaccine candidate based on its proprietary oral vaccine platform, VAAST. “Vaxart’s proprietary technology has been clinically proven in humans, and the ability to make an oral vaccine to meet this current public health threat is very important to all of us at Vaxart,” said Sean Tucker, Ph.D., chief scientific officer of Vaxart. “The results of our recently published influenza challenge study demonstrated that our oral tablet vaccine primarily protects through mucosal immunity, a potential key factor when targeting mucosal pathogens such as this new coronavirus.” Under the program, Vaxart plans to generate vaccine candidates based on the published genome of the 2019 Novel Coronavirus and evaluate them in preclinical models for their ability to generate both mucosal and systemic immune responses.
AIM stock was up over 8% in after-hours trading.
On February 11, 2020, AIM ImmunoTech announced the filing of three provisional patent applications related to its drug candidate Ampligen in the company’s efforts toward joining the global health community in the fight against the deadly Wuhan coronavirus that has so far infected approximately 40,000 people and killed almost one thousand, primarily in China. Coronaviruses are a large family of viruses, including the deadly Severe Acute Respiratory Syndrome, or SARS. After a 2002 SARS outbreak in the Guangdong province of southern China caused more than 8,000 cases and more than 800 deaths, the United States’ National Institutes of Health contracted studies to evaluate potential treatments for SARS. Ampligen achieved a 100% survival rate – as compared to 100% mortality – at clinically achievable human dosage levels in animal experiments. The SARS virus is very similar in key RNA sequences to the Wuhan coronavirus, and the company expects Ampligen to be similarly effective with the Wuhan coronavirus. AIM believes that Ampligen has the potential to be both an early-onset treatment for and prophylaxis against the Wuhan coronavirus, which originated in China before quickly spreading to other countries. The company’s three provisional patent applications include: Ampligen as a therapy for the Wuhan coronavirus; Ampligen as part of a proposed intranasal universal coronavirus vaccine that combines Ampligen with inactivated Wuhan coronavirus, conveying immunity and cross-protection and; a high-volume manufacturing process for Ampligen. Under the Patent Cooperation Treaty of 1970, which provides international protections for patents, the three provisional patent applications can convert to international patent applications based on the date of their filings. Alternatively, direct national filings in many countries are possible under the Paris Convention for the Protection of Industrial Property of 1883 – an international agreement. China, the epicenter of the epidemic, is a signatory of both the treaty and the agreement.
INO stock was up more than 7% in after-hours trade.
On January 30, 2020, Inovio announced that it is collaborating with Beijing Advaccine to advance the development in China of INO-4800, Inovio’s vaccine against the recently emerged strain of coronavirus that has killed numerous people and infected thousands more in China to date. Inovio recently announced that it is developing INO-4800 through Phase 1 human testing in the U.S. to evaluate safety and immunogenicity with the support of an initial grant up to $9M from the Coalition for Epidemic Preparedness Innovations, or CEPI. Inovio plans to rapidly develop INO-4800 against the new coronavirus and has already started preclinical testing and preparations for clinical product manufacturing. The goal of this collaboration is to leverage Advaccine’s expertise to run a Phase 1 trial in China in parallel with Inovio’s clinical development efforts in the U.S. Inovio and Advaccine will also work together to attract additional grant funding and further collaborations with larger vaccine companies in China to increase the speed of future testing of INO-4800. Inovio’s participation in this developing effort is based on the suitability of its DNA medicine platform to rapidly develop vaccines against emerging viruses with pandemic potential, proven vaccine development capabilities, and ability to generate countermeasures against previous pandemic threats. In a recently published paper in Lancet Infectious Diseases, Inovio’s Phase 1 study of INO-4700, its MERS-CoV vaccine, demonstrated it was well-tolerated and furthermore induced high levels of antibody responses in approximately 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. Durable antibody responses to INO-4700 were also maintained through 60 weeks following dosing.